1. Home
  2. GRF vs GANX Comparison

GRF vs GANX Comparison

Compare GRF & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

HOLD

Current Price

$10.33

Market Cap

39.9M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

N/A

Current Price

$1.74

Market Cap

88.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRF
GANX
Founded
1989
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
88.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GRF
GANX
Price
$10.33
$1.74
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
4.1K
326.1K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
31.46
EPS
1.16
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.60
$1.53
52 Week High
$11.85
$4.34

Technical Indicators

Market Signals
Indicator
GRF
GANX
Relative Strength Index (RSI) 49.09 N/A
Support Level $9.69 N/A
Resistance Level $10.64 N/A
Average True Range (ATR) 0.12 0.00
MACD -0.02 0.00
Stochastic Oscillator 51.97 0.00

Price Performance

Historical Comparison
GRF
GANX

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: